iBio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio’s patented Machine-Learning Antibody Engine. iBio plans to rapidly advance testing of this molecule and additional candidates in more complex and disease relevant models.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IBIO:
- iBio Expands Pipeline with New Antibody Agreement
- iBio expands cardiometabolic, obesity treatment development program
- iBio initiated with a Buy at Lucid Capital
- iBio announces the appointment of Arkowitz, Parada to board of directors
- iBio reports Q1 EPS (46c), consensus (48c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
